This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Review paper

Long-term safety of ketamine and esketamine in treatment of depression

Volume: 21, Issue: 6, Pages: 777 - 787
Published: Apr 13, 2022
Abstract
Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019. Here we review what is known about the long-term safety of both racemic ketamine and esketamine as therapies for psychiatric disorders.In this article, we conducted a safety review of ketamine and esketamine. In looking at ketamine and esketamine long-term...
Paper Details
Title
Long-term safety of ketamine and esketamine in treatment of depression
Published Date
Apr 13, 2022
Volume
21
Issue
6
Pages
777 - 787
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.